Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry

Annals of the New York Academy of Sciences

Volumn 1054, Issue , 2005, Pages 350-357

  Fischer, Roland ^a,b   Piga, Antonio ^c   Harmatz, Paul ^b   Nielsen, Peter ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b CHILDREN S HOSPITAL OAKLAND   (United States)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Biosusceptometry; Deferiprone; Desferrioxamine; Liver iron; Molar efficacy; SQUID

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE;

ADOLESCENT; ADULT; AGED; BIOMAGNETIC LIVER SUSCEPTOMETRY; BLOOD TRANSFUSION; BODY WEIGHT; CHILD; CONFERENCE PAPER; DRUG EFFICACY; EUROPE; HUMAN; IRON CHELATION; IRON STORAGE; LIVER BIOPSY; LIVER WEIGHT; MAJOR CLINICAL STUDY; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; THALASSEMIA; WESTERN HEMISPHERE;

EID: 29744467874     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1345.043     Document Type: Conference Paper

References (27)

1. MODELL, B. & V. BERDOUKAS. 1984. The Clinical Approach to Thalassemia. Grune & Stratton. London, pp. 163-169, 215.
2. BRITTENHAM, G.M., D.E. FARRELL, J.W. HARRIS, et al. 1982. Magnetic susceptibility measurement of human iron stores. N. Engl. J. Med. 307: 1671-1675.
3. ANGELUCCI, E., G.M. BRITTENHAM, C.E. MCLAREN, et al. 2000. Hepatic iron concentration and total body iron store in thalassemia major. N. Engl. J. Med. 343: 327-331.
4. OLEVIERI, N.F., G.M. BRITTENHAM, D. MATSUI, et al. 1995. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N. Engl. J. Med. 332: 918-922.
5. HOFFBRAND, A.V., F. AL-REFAIE, B. DAVIS, et al. 1998. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 91: 295-300.
6. FISCHER, R., F. LONGO, P. NIELSEN, et al. 2003. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with β-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br. J. Haematol. 121: 918-948.
7. BORGNA-PIGNATTI, C., S. RUGOLOTTO, P. DE STEFANO, et al. 2004. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89: 1187-1193.
8. OLEVIERI, N.F. & G.M. BRITTENHAM. 1997. Iron-chelating therapy and the treatment of thalassemia. Blood 89: 739-761.
9. BUTENSKY, E., R. FISCHER, M. HUDES, et al. 2005. Variability in hepatic iron concentration in percutaneous needle biopsy specimens from patients with transfusional hemosiderosis. Am. J. Clin. Pathol. 123: 146-152.
10. ZUYDERHOUDT, P.M., P. HENGEVELD, J. VAN GOOL & G.G. JÖRNING. 1978. A method for measurement of liver iron fractions in needle biopsy specimens and some results in acute liver disease. Clin. Chim. Acta 86: 313-321.
11. FISCHER, R. 1998. Liver iron biosusceptometry. In Magnetism in Medicine-A Handbook. W. Andrae & H. Nowak, Eds.: 286-301. Wiley-VCH. Berlin.
12. PORTER, J.B., M.S. JASWON & E.R. HUEHNS. 1989. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br. J. Haematol. 73: 403-409.
13. FARRELL, D.E. 1983. Assessment of iron in human tissue: the magnetic biopsy. In Biomagnetism: An Interdisciplinary Approach. S.J. Williamson, G.L. Romani, L. Kaufman & I. Modena, Eds.: 483-499. Plenum. New York.
14. FISCHER, R., C.D. TIEMANN, R. ENGELHARDT, et al. 1999. Assessment of iron stores in children with transfusion siderosis by biomagnetic liver susceptometry. Am. J. Hematol. 60: 289-299.
15. FISCHER, R., F. LONGO, R. ENGELHARDT, et al. 2003. Liver volumes in patients with β-thalassemia major. Biomark. Environ. Suppl. 1: 58-60.
16. BERGERON, R.J., R.R. STREIFF, J. WIEGAND, et al. 1992. A comparison of the iron-clearing properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine. Blood 79: 1882-1890.
17. ST. PIERRE, T.G., P.R. CLARK, W. CHUA-ANUSORN, et al. 2005. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105: 855-861.
18. JENSEN, P.D., F.T. JENSEN, T. CHRISTENSEN & J. ELLEGAARD. 1994. Non-invasive assessment of tissue iron overload in the liver by magnetic resonance imaging. Br. J. Haematol. 87: 171-184.
19. WOOD, J.C., C. ENRIQUEZ, N. GHUGRE, et al. 2005. MRI R2 and R1* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle-cell disease patients. Blood 106: 1460-4065.
20. GANDON, Y., D. OLIVIÉ, D. GUYADER, et al. 2004. Noninvasive assessment of hepatic iron stores by MRI. Lancet 363: 357-362.
21. ANDERSON, L.J., S. HOLDEN, B. DAVIS, et al. 2001. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur. Heart J. 22: 2171-2179.
22. ROPERT-BOUCHET, M., B. TURLIN, G. GRAHAM, et al. 2005. Drying methods affect the wet:dry weight ratio of liver tissue samples and impact liver iron content (LIC) measurements. BioIron 2005, Prague, P274.
23. CIBA-GEIGY. 1977. In Wissenschaftliche Tabellen Geigy. Ciba-Geigy, Ltd. Basel.
24. NIELSEN, P., R. FISCHER, R. ENGELHARDT & J. DÜLLMANN. 2003. Diagnosis of hereditary haemochromatosis using non-invasive methods. Transfus. Med. Hemother. 30: 27-36.
25. ANGELUCCI, E., P. MURETTO, A. NICOLUCCI, et al. 2002. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 100: 17-21.
26. NIELSEN, P., U. KORDES, R. FISCHER, et al. 2002. SQUID-Biosuszeptometrie bei Eisenueberladungskrankheiten in der Haematologie. Klin. Paediatr. 214: 218-222.
27. CHOUDHRY, V.P., H.P. PATI, A. SAXENA & A.N. MALAVIYA. 2004. Deferiprone, efficacy and safety. Indian J. Pediatr. 71: 213-216.